Treatment of Physician’s Choice (TPC)
Any monotherapy (chemotherapy,
hormonal, biological)* or supportive
care only
†
Study 305 (EMBRACE): Study Schema
Patients (N=762)
•
Locally recurrent or
MBC
•
2-5 prior
chemotherapies
−
≥2 for advanced disease
−
Prior anthracycline and
taxane
•
Progression ≤6 months
of last chemotherapy
•
Neuropathy ≤grade 2
•
ECOG ≤2
Eribulin
1.23 mg/m
2
,
*
2-5 min IV
Day 1 & 8 q21 days
Randomization 2:1
Primary
End Point
● OS
Secondary
End Points
● PFS
● ORR
● Safety
3º línea 43%
4º línea 32%
